Growing Diagnostic Portfolio ALPCO's recent launches of FDA 510(k) cleared immunoassays, such as the Calprotectin Immunoturbidimetric Assay, demonstrate ongoing product development in gastrointestinal diagnostics, indicating opportunities to expand into labs seeking innovative and reliable diagnostic solutions.

Strategic Partnerships The company's collaborations with Dynex Technologies and GeneProof highlight its focus on automated and multiplex diagnostic testing, presenting prospects to introduce complementary automation and multiplexing solutions to existing and new laboratory clients.

Global Expansion Expanding its gastrointestinal diagnostic offerings in Europe signals ALPCO’s intent for international growth, offering potential sales avenues through global distributors and regional laboratories interested in high-quality molecular diagnostics.

Market Positioning Positioned as a dedicated provider of molecular and immunodiagnostic products, ALPCO’s focus on innovative, user-friendly, and reliable solutions aligns with the increasing demand for accurate diagnostics, creating opportunities to serve labs prioritizing quality and compliance.

Product Development Focus With a strategic focus on launching FDA-approved assays and automating complex diagnostic tests, ALPCO presents opportunities to partner with hospitals, research institutes, and commercial labs looking for advanced, scalable diagnostic technologies.